Effect of alpha‐lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss
Archives of Gynecology and Obstetrics · 25.02.2026 · 313 (1)
DOI: 10.1007/s00404-026-08365-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 25.02.2026. Verfasst von Chiara Tersigni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168, Rome, Italy. chiara.tersigni@policlinicogemelli.it. Hauptthemen laut MEDLINE: Thioctic Acid, Abortion, Habitual, Inositol, Endometrium. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore.
Abstract (Originalsprache)
Purpose
The aim of this study was to investigate the effect of oral administration of a combination of alpha- lipoic acid (ALA) and myo-inositol (Myo) on serum and endometrial inflammation of women with unexplained recurrent pregnancy loss (uRPL).
Methods
Serum and endometrial levels of Nacht leucine-rich-repeat protein-3 (NLRP-3) and High Mobility Group Box 1 (HMGB-1) were analyzed by ELISA in women with unexplained Recurrent Pregnancy Loss (uRPL) (n = 31) and in control women who had had at least one uncomplicated pregnancy at term (n = 10) before and after daily oral administration of a commercial combination of ALA and Myo. Results uRPL women had higher serum levels (p < 0.01) and endometrial content (p < 0.0001) of HMGB-1 than controls while no difference was observed regarding NALP3. Oral administration of ALA and Myo for three months significantly decreased pre-treatment serum levels of NLRP-3 (p < 0.0001) and HMGB-1 (p < 0.0001), as well as endometrial content of NLRP-3 (p < 0.001) and HMGB-1 (p < 0.0001) in uRPL women, similar to those found in controls.
Conclusion
Women with uRPL have increased systemic and endometrial inflammation than controls. Oral administration of ALA and Myo could modulate serum and endometrial levels of NLRP-3 and HMGB-1 in uRPL women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168, Rome, Italy. chiara.tersigni@policlinicogemelli.it.
- Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43124, Parma, Italy.
- Department of Mother and Child, University Hospital of Parma, Via Gramsci, 14, 43124, Parma, Italy.
- Università Cattolica del Sacro Cuore, L.go F.Vito 1, 00168, Rome, Italy.
- Istituto Scientifico Internazionale Paolo VI, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168, Rome, Italy.
- Department of Mother and Child, Azienda USL-IRCCS, di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
Förderung
- Università Cattolica del Sacro Cuore
Zitieren
APA
Tersigni, C., Street, M. E., Castellani, R., Di Nicuolo, F., Onori, M., Catellani, C., Barbaro, G., Ticconi, C., & Di Simone, N. (2026). Effect of alpha‐lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss. Archives of Gynecology and Obstetrics, 313(1). https://doi.org/10.1007/s00404-026-08365-8
Vancouver
Tersigni C, Street ME, Castellani R, Di Nicuolo F, Onori M, Catellani C, et al. Effect of alpha‐lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss. Archives of Gynecology and Obstetrics. 2026;313(1). doi:10.1007/s00404-026-08365-8
BibTeX
@article{Tersigni2026,
author = {Tersigni, Chiara and Street, Maria Elisabeth and Castellani, Roberta and Di Nicuolo, Fiorella and Onori, Marianna and Catellani, Cecilia and Barbaro, Greta and Ticconi, Carlo and Di Simone, Nicoletta},
title = {Effect of alpha‐lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss},
journal = {Archives of Gynecology and Obstetrics},
year = {2026},
volume = {313},
number = {1},
doi = {10.1007/s00404-026-08365-8}
}
EUVIMED